{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T20:14:06Z","timestamp":1771532046921,"version":"3.50.1"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.phrs.2022.106064","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T11:17:33Z","timestamp":1641467853000},"page":"106064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects"],"prefix":"10.1016","volume":"176","author":[{"given":"Stefano","family":"Rusconi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Saladini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Concetta","family":"Bellocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Gazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Vichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Foc\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria M.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Gabrieli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.phrs.2022.106064_bib1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1128\/JVI.75.2.579-588.2001","article-title":"Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140","volume":"75","author":"Trkola","year":"2001","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106064_bib2","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1128\/JVI.73.5.4145-4155.1999","article-title":"Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5","volume":"73","author":"Olson","year":"1999","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.phrs.2022.106064_bib3","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1128\/AAC.00699-06","article-title":"Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1","volume":"50","author":"Murga","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.phrs.2022.106064_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1473-3099(10)70319-4","article-title":"European Consensus Group on clinical management of tropism testing. European guidelines on the clinical management of HIV-1 tropism testing","volume":"11","author":"Vandekerckhove","year":"2011","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2022.106064_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jiq030","article-title":"Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients","volume":"203","author":"Swenson","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.phrs.2022.106064_bib6","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/jac\/dkaa178","article-title":"In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients","volume":"75","author":"Saladini","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.phrs.2022.106064_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15284336.2018.1452842","article-title":"PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection","volume":"19","author":"Dhody","year":"2018","journal-title":"HIV Clin. Trials"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822000093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822000093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:28:03Z","timestamp":1760912883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":7,"alternative-id":["S1043661822000093"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106064","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106064"}}